PepGen (NASDAQ:PEPG) Stock Price Target Raised at Wedbush

PepGen (NASDAQ:PEPG) had its price objective increased by Wedbush from $4.00 to $10.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush‘s price target would indicate a potential upside of 116.92% from the stock’s previous close.

Several other brokerages have also commented on PEPG. Weiss Ratings raised shares of PepGen from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 22nd. Wall Street Zen raised shares of PepGen from a “sell” rating to a “hold” rating in a research report on Saturday. HC Wainwright restated a “buy” rating on shares of PepGen in a research note on Wednesday, September 9th. Finally, Bank of America upgraded shares of PepGen from an “underperform” rating to a “neutral” rating and raised their price target for the stock from $2.50 to $6.00 in a research note on Tuesday. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, PepGen currently has an average rating of “Moderate Buy” and a consensus price target of $11.50.

PepGen Price Performance

Shares of PepGen stock opened at $4.61 on Wednesday. The firm has a market cap of $319.29 million, a PE ratio of -3.52 and a beta of 2.02. PepGen has a 1 year low of $1.31 and a 1 year high of $7.80. The stock has a fifty day moving average price of $2.69 and a 200-day moving average price of $2.98.

PepGen (NASDAQ:PEPG) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.01). As a group, equities analysts anticipate that PepGen will post -1.11 EPS for the current fiscal year.

Institutional Investors Weigh In On PepGen

Several large investors have recently added to or reduced their stakes in the company. Group One Trading LLC bought a new stake in PepGen in the 1st quarter valued at about $77,000. Seven Fleet Capital Management LP bought a new position in PepGen during the first quarter worth about $105,000. Rangeley Capital LLC boosted its position in PepGen by 88.1% during the first quarter. Rangeley Capital LLC now owns 68,096 shares of the company’s stock worth $121,000 after purchasing an additional 31,896 shares during the period. Persistent Asset Partners Ltd purchased a new position in shares of PepGen in the second quarter worth about $171,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of PepGen in the second quarter worth about $202,000. Hedge funds and other institutional investors own 58.01% of the company’s stock.

Key PepGen News

Here are the key news stories impacting PepGen this week:

• Positive Sentiment: PepGen said the 10 mg/kg dose in its Phase 2 FREEDOM2-DM1 trial showed the highest reported splicing correction and improvements across multiple functional measures—an encouraging signal for its DM1 drug and the main catalyst behind investor interest. Article: PepGen Announces Positive Phase 2 FREEDOM2-DM1 Results
• Positive Sentiment: Bank of America upgraded PEPG from “underperform” to “neutral” and raised its price target to $6 from $2.50, reflecting a more favorable view of the shares. Article: Bank of America Stock Recommendations
• Neutral Sentiment: PepGen reported $104.8 million in cash, providing funding for continued development, though the company remains loss-making. Article: PepGen Reports Phase 2 Results and Cash Position
• Negative Sentiment: The company proposed a $125 million public stock offering. The financing could strengthen its balance sheet, but issuing shares may dilute existing shareholders. Article: PepGen Launches $125M Public Stock Offering
• Negative Sentiment: PepGen reported a quarterly loss of $0.28 per share, slightly wider than the $0.27 loss analysts expected. Article: PepGen Reports Third Quarter 2026 Financial Results
• Negative Sentiment: Options trading included a sharp increase in put purchases, which may indicate heightened hedging or bearish positioning. Article: Traders Purchase Put Options on PepGen

About PepGen

PepGen Inc. is a clinical-stage biotechnology company developing genetic medicines for serious neuromuscular diseases. The company’s technology is designed to improve the delivery of oligonucleotide therapeutics into skeletal and cardiac muscle, with the goal of addressing diseases caused by genetic mutations or abnormal RNA processing. PepGen’s platform, known as Enhanced Delivery Oligonucleotides (EDO), combines therapeutic oligonucleotides with proprietary peptides intended to facilitate their distribution into muscle tissue.